Amgen vs HDFC Bank: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. HDFC Bank was founded in 1994 by Hasmukhbhai Parekh and is led by Sashidhar Jagdishan.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
HDFC Bank
Hasmukhbhai Parekh
Hasmukhbhai Thakordas (H.T.) Parekh founded Housing Development Finance Corporation (HDFC) in 1977, at age 66, after a long career at ICICI.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
HDFC Bank
- Aditya Puri1994–2020
Managing Director
Over 26 years as CEO, he built HDFC into India's largest and most highly valued private sector bank, maintaining pristine asset quality throughout multiple economic cycles.
Source - Sashidhar Jagdishan2020–present
Managing Director and Chief Executive Officer
Steered the bank through the RBI technology restrictions and the largest merger in Indian banking, while keeping gross NPAs near 1.2%.
Source - Atanu Chakraborty2021–2026
Part-time Chairman
Former Economic Affairs Secretary who chaired the board through the HDFC Ltd merger; resigned on March 18, 2026, citing ethical concerns. Keki Mistry served as interim chairman until Rajiv Kumar's appointment.
Source - Rajiv Kumar2026–present
Part-time Chairman
He managed the complex post-merger integration processes to ensure the massive combined loan book maintained strict asset quality.
Source
Timeline: Amgen and HDFC Bank side by side
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1994HDFC Bank
HDFC Bank Incorporated
HDFC Bank is incorporated as one of India's new private-sector banks.
1995HDFC Bank
Banking Operations Begin
The bank begins operations and builds a private-sector banking franchise.
2000HDFC Bank
Times Bank Merger
HDFC Bank merges with Times Bank, one of its early scale-building deals.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2020HDFC Bank
Sashidhar Jagdishan Becomes CEO
Sashidhar Jagdishan succeeds Aditya Puri as managing director and CEO in October 2020.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2023HDFC Bank
HDFC Ltd Merger Completed
HDFC Bank completes the merger with parent HDFC Ltd, creating a much larger banking balance sheet.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026HDFC Bank
FY2025-26 Net Revenues Reach INR 1,91,218.60 Crore
HDFC Bank reports ~$22.2 billion (INR 1,91,218.60 crore) in net revenues and ~$8.66 billion (INR 74,671.30 crore) in profit after tax.
2026HDFC Bank
Rajiv Kumar Becomes Chairman
After Atanu Chakraborty resigned in March 2026, the RBI approved Rajiv Kumar as part-time chairman effective July 15, 2026.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
HDFC Bank
- HDFC Ltd. (Reverse Merger)2023Undisclosed
- Centurion Bank of Punjab2008Undisclosed
Questions about Amgen vs HDFC Bank
Who is the CEO of Amgen Inc. and HDFC Bank Limited?
Amgen Inc. is led by Robert A. Bradway and HDFC Bank Limited is led by Sashidhar Jagdishan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs HDFC Bank Limited?
Amgen Inc. was founded in 1980 — 14 years before HDFC Bank Limited, which was founded in 1994. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger HDFC Bank Limited.
How many employees does Amgen Inc. have compared to HDFC Bank Limited?
Amgen Inc. employs approximately 31,500 people, while HDFC Bank Limited employs approximately 211,178. HDFC Bank Limited has the larger workforce at 211,178 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and HDFC Bank Limited headquartered?
Amgen Inc. is headquartered in United States and HDFC Bank Limited is headquartered in India. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amgen Inc. and HDFC Bank Limited?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. HDFC Bank Limited was founded by Hasmukhbhai Parekh.
Which company has a longer operating history — Amgen Inc. or HDFC Bank Limited?
Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. HDFC Bank Limited has been in operation for around 32 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs HDFC Bank overview